Targeting monocytes/macrophages in the treatment of rheumatoid arthritis

Rheumatology (Oxford). 2013 Apr;52(4):590-8. doi: 10.1093/rheumatology/kes304. Epub 2012 Nov 30.


Biotherapies have revolutionized the treatment of RA. However, much work is needed to understand all the mechanisms of these biotherapies, and alternatives are needed to circumvent adverse effects and the high cost of these long-lasting treatments. In this article we outline some of the approaches we have used to target monocytes/macrophages as major components of inflammation and bone homeostasis. We also discuss how anti-TNF-α antibodies target monocytes/macrophages in the complex mechanisms contributing to inhibition of inflammation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / therapy*
  • Dendrimers
  • Gene Silencing / drug effects*
  • Group IV Phospholipases A2 / genetics*
  • Humans
  • Macrophages / enzymology*
  • Molecular Targeted Therapy / methods*
  • Monocytes / enzymology*
  • RNA, Small Interfering / therapeutic use*
  • Tumor Necrosis Factor-alpha / immunology


  • Dendrimers
  • RNA, Small Interfering
  • Tumor Necrosis Factor-alpha
  • Group IV Phospholipases A2